scholarly journals The main impacts of COVID-19 on parkinson’s disease patients

2021 ◽  
Author(s):  
Mariana Silva Regadas ◽  
Guilherme Albuquerque de Araújo Costa ◽  
Myrela Murad Sampaio

Background: COVID-19 patients with chronic diseases and comorbidities are more susceptible to the severe form of the infection. Neurological symptoms are reported by some patients infected by the virus and research seeks the relationship between the virus and neurological diseases, such as Parkinson’s Disease (PD). Objectives: To understand how COVID-19 and its effects affect patients with PD. Methods: Integrative review with search on Google Scholar, Scielo, PubMed and Science Direct platforms through an online scenario, selected articles from the years 2020 and 2021. Results: SARS-CoV-2 frequently undergo mutations, causes damage and inflammation. There are reports of symptoms such as anosmia, ageusia and headache. Anosmia stands out for its relationship with one initial symptom of PD, hyposmia. As the majority of PD patients are elderly and have comorbidities, there is a higher risk of being infected. Some patients with PD infected by the virus report worsening in motor and non-motor symptoms and such worsening can occur due to systemic inflammation, stress and the measures to contain the pandemic. Conclusions: PD is not a risk factor for COVID-19, however patients may experience worsening symptoms due to comorbidities, old age and stress caused by the pandemic. Strategies that reduce stress are options for maintaining the health of patients with PD.

2013 ◽  
Vol 71 (4) ◽  
pp. 216-219 ◽  
Author(s):  
Carlos Cosentino ◽  
Yesenia Nuñez ◽  
Luis Torres

Introduction: Non-motor symptoms in Parkinson's disease are often not well recognized in clinical practice. Non-motor symptoms questionnaire (NMSQuest) is a simple instrument that allows patients or caregivers to report non-motor symptoms in a practical manner. Objective: We attempted to determine the prevalence of non-motor symptoms in three hundred Parkinson's disease outpatients. Results: The mean total non-motor symptoms was 12.41, ranging from 0 to 27 of a maximum of 30. At least one was present in 99.3% of patients. A progressive increase in mean total score was observed across each 5-year interval. Depression domain scored the most “positive” answers while urinary and anxiety /memory were secondly and thirdly most prevalent respectively. Conclusion: The large number of patients included in this study allowed evaluation of the occurrence of non-motor symptoms in early and advanced disease in addition to the relationship of these kinds of symptoms with progression of disease.


1970 ◽  
Vol 21 (1) ◽  
pp. 12-17
Author(s):  
M Ahmed Ali ◽  
Anisul Haque ◽  
AKM Anwarulla ◽  
Quamruddin Ahmad

Parkinson's disease is a disease of motor manifestations but non-motor symptoms are also common in Parkinson's disease. Little emphasis is put on non-motor symptoms of PD and there is little data on the relationship of non-motor symptoms to different aspects of the patient and the disease. In this study the relationship of non-motor symptoms to age at onset, duration and stage of the disease, and dose and duration of levodopa use are studied.128 patients of PD were studied for non-motor symptoms. 111 patients had different types of sensory, autonomic or psychiatric symptoms. Sensory and autonomic symptoms were significantly more common in patients with early age of disease onset and more prolonged duration of the disease, but psychiatric symptoms had no relationship with these factors. In this study it was also found that the frequencies of non-motor symptoms were related to the stage of the disease, longer the duration of the disease more and more non-motor symptoms appear so that 100% patients in stage 5 of the disease had non-motor symptoms. Also sensory and autonomic symptoms were significantly more common in patients with longer duration and higher dose of levodopa use but psychiatric symptoms were significantly commoner in patients with prolonged duration of levodopa use but not to dose of levodopa used.   doi: 10.3329/taj.v21i1.3211 TAJ 2008; 21(1): 12-17


2017 ◽  
Vol 11 (3) ◽  
pp. 171-175 ◽  
Author(s):  
Jian Ding ◽  
Si-Ming Jiang ◽  
Yong-Sheng Yuan ◽  
Qing Tong ◽  
Li Zhang ◽  
...  

2019 ◽  
Vol 12 (4) ◽  
pp. 673-678 ◽  
Author(s):  
Sheera F. Lerman ◽  
Gila Bronner ◽  
Oren S. Cohen ◽  
Sandra Elincx-Benizri ◽  
Hanna Strauss ◽  
...  

2017 ◽  
Vol 124 (7) ◽  
pp. 863-867 ◽  
Author(s):  
Marcelo D. Mendonça ◽  
Tania Lampreia ◽  
Rita Miguel ◽  
André Caetano ◽  
Raquel Barbosa ◽  
...  

2021 ◽  
pp. 1-15
Author(s):  
Eduardo Tolosa ◽  
Georg Ebersbach ◽  
Joaquim J. Ferreira ◽  
Olivier Rascol ◽  
Angelo Antonini ◽  
...  

Background: A greater understanding of the everyday experiences of people with Parkinson’s disease (PD) and their carers may help improve clinical practice. Objective: The Parkinson’s Real-world Impact assesSMent (PRISM) study evaluated medication use, health-related quality of life (HRQoL) and the use of healthcare resources by people with PD and their carers. Methods: PRISM is an observational cross-sectional study, in which people with PD and their carers completed an online survey using structured questionnaires, including the Parkinson’s Disease Quality of Life Questionnaire (PDQ-39), Non-Motor Symptoms Questionnaire (NMSQuest) and Zarit Burden Interview (ZBI). Results: Data were collected from 861 people with PD (mean age, 65.0 years; mean disease duration, 7.7 years) and 256 carers from six European countries. People with PD reported a large number of different co-morbidities, non-motor symptoms (mean NMSQuest score, 12.8), and impaired HRQoL (median PDQ-39 summary score, 29.1). Forty-five percent of people with PD reported at least one impulse control behaviour. Treatment patterns varied considerably between different European countries. Levodopa was taken in the last 12 months by 85.9% of participants, and as monotherapy by 21.8% . Carers, who were mostly female (64.8%) and the partner/spouse of the person with PD (82.1%), reported mild to moderate burden (mean ZBI total score, 26.6). Conclusions: The PRISM study sheds light on the lives of people with PD and those who care for them, re-emphasising the many challenges they face in everyday life. The study also provides insights into the current treatment of PD in Europe.


Sign in / Sign up

Export Citation Format

Share Document